Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis

We attempted to determine whether various cytokine levels in the serum and synovial fluid (SF) of rheumatoid arthritis (RA) patients are influenced by the performance of filtration leukocytapheresis (LCP). The filtration LCP procedure that used a Cellsorba® column (LCP group: n=22; responder subgroup: n=17, non‐responder subgroup: n=5) or sham apheresis (control group; n=7) was repeated three times at 1‐week intervals. Serum (LCP group, n=22; control group, n=7) and SF (LCP group, n=6; control group, n=3) samples were collected before and after LCP. Levels of tumor necrosis factor α (TNFα), interleukins (IL‐1β, IL–2, IL‐6, IL‐8, IL‐10, and IL‐15), granulocyte–macrophage colony–stimulating factor (GM‐CSF), monocyte chemoattractant protein–1 (MCP‐1), RANTES were measured by an enzyme‐linked immunosorbent assay. Serum TNFα, IL‐15, and RANTES were significantly reduced only in the LCP group. Serum IL‐10 significantly increased only in the LCP group. In the LCP subgroup, serum IL‐15, GM‐CSF, and RANTES levels were reduced significantly, while serum IL‐10 levels increased significantly only in the responder group after treatment. Serum TNFα levels were reduced significantly in both subgroups. Changes in serum IL‐10 correlated positively with the improvement of patient's assessment of pain and global severity, and physician's assessment of global severity. These results indicate that the removal of leukocytes from the peripheral blood of RA patients provokes dynamic changes in some cytokine levels in the serum and/or synovial fluid. These changes may explain some of the mechanisms by which the articular symptoms are improved by filtration LCP. J. Clin. Apheresis. 16:74–81, 2001. © 2001 Wiley‐Liss, Inc.

[1]  F. Ohsuzu,et al.  Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. , 1999, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[2]  T. Hidaka,et al.  Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. , 1999, Arthritis and rheumatism.

[3]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[4]  J. Hamilton,et al.  Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. , 1998, Journal of immunology.

[5]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[6]  H. Makino,et al.  Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[7]  G. Boivin,et al.  Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. , 1998, Journal of immunology.

[8]  R. Strieter,et al.  Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. , 1998, The Journal of clinical investigation.

[9]  I. McInnes,et al.  Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. , 1998, Journal of immunology.

[10]  C. Jorgensen,et al.  Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. , 1998, Journal of immunology.

[11]  H. Makino,et al.  The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[12]  I. McInnes,et al.  Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis , 1997, Nature Medicine.

[13]  L. Joosten,et al.  Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. , 1997, Arthritis and rheumatism.

[14]  A. Al-Dalaan,et al.  CD4+ T cell inducible immunoregulatory cytokine response in rheumatoid arthritis. , 1996, The Journal of rheumatology.

[15]  I. McInnes,et al.  The role of interleukin–15 in T–cell migration and activation in rheumatoid arthritis , 1996, Nature Medicine.

[16]  J. Banchereau,et al.  Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[17]  M. Feldmann,et al.  High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. , 1995, Arthritis and rheumatism.

[18]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[19]  M. Burdick,et al.  Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. , 1995, The Journal of clinical investigation.

[20]  J. Dayer,et al.  Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis , 1995 .

[21]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[22]  A. Hajeer,et al.  RANTES role in rheumatoid arthritis , 1994, The Lancet.

[23]  P. Heinrich,et al.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense. , 1993, The Clinical investigator.

[24]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[25]  S. McColl,et al.  Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. , 1993, The Journal of biological chemistry.

[26]  R. de Waal Malefyt,et al.  IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. , 1992, Journal of immunology.

[27]  M. Burdick,et al.  Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. , 1992, The Journal of clinical investigation.

[28]  F. Breedveld,et al.  T Cells Cloned from Human Rheumatoid Synovial Membrane Functionally Represent the Th 1 Subset , 1992, Scandinavian Journal of Immunology.

[29]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[30]  T. Mosmann,et al.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Goeddel,et al.  Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES , 1990, Nature.

[32]  T. Mosmann,et al.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones , 1989, The Journal of experimental medicine.

[33]  G. Firestein,et al.  Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. , 1989, The Journal of clinical investigation.

[34]  G. Firestein,et al.  Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis , 1988, The Journal of experimental medicine.

[35]  J. Symons,et al.  CORRELATION OF PLASMA INTERLEUKIN 1 LEVELS WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS , 1988, The Lancet.

[36]  D. Heinegård,et al.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. , 1988, Arthritis and rheumatism.

[37]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.

[38]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[39]  P. Rebulla,et al.  Leukocyte depletion of red cell units at the bedside by transfusion through a new filter , 1987, Transfusion.

[40]  M. Piazza,et al.  HEPATITIS B NOT TRANSMISSIBLE VIA FÆCAL-ORAL ROUTE , 1975, The Lancet.

[41]  O. Steinbrocker,et al.  Therapeutic criteria in rheumatoid arthritis. , 1949, Journal of the American Medical Association.